Suppr超能文献

危重症肥胖患者氨基糖苷类药物的药代动力学变化及剂量调整:文献综述

Pharmacokinetic changes and dosing modification of aminoglycosides in critically ill obese patients: a literature review.

作者信息

Velissaris Dimitrios, Karamouzos Vasilios, Marangos Markos, Pierrakos Charalampos, Karanikolas Menelaos

机构信息

Internal Medicine Department, University Hospital of Patras, Rion 26500, Greece.

Intensive Care Department, Brugmann University Hospital, Brussels 1030, Belgium.

出版信息

J Clin Med Res. 2014 Aug;6(4):227-33. doi: 10.14740/jocmr1858w. Epub 2014 May 22.

Abstract

The objective of the paper is to review the literature and provide recommendations for use of aminoglycoside antibiotics in critically ill obese patients. Literature search in PubMed for all articles on the use of aminoglycosides in critically ill obese patients was conducted, and all articles related to pharmacokinetics in obesity were reviewed. Bibliographies of all searched manuscripts were also reviewed in an attempt to find additional references. Although aminoglycoside pharmacokinetics have been described in detail, data on aminoglycoside use and appropriate dose modification in critically ill obese patients are very limited. Knowledge on aminoglycoside pharmacokinetics and use in critically ill obese patients is incomplete. Pathophysiologic changes in obesity can result in sub- or supra-therapeutic aminoglycoside plasma concentrations, especially in the presence of sepsis. Rigorous clinical studies are needed to establish aminoglycoside dosing guidelines in critically ill obese patients with sepsis.

摘要

本文的目的是回顾文献,并为危重症肥胖患者使用氨基糖苷类抗生素提供建议。我们在PubMed上检索了所有关于危重症肥胖患者使用氨基糖苷类药物的文章,并对所有与肥胖患者药代动力学相关的文章进行了综述。我们还查阅了所有检索到的手稿的参考文献,试图找到更多的参考文献。尽管氨基糖苷类药物的药代动力学已经有了详细的描述,但关于危重症肥胖患者使用氨基糖苷类药物及适当剂量调整的数据非常有限。关于氨基糖苷类药物在危重症肥胖患者中的药代动力学和使用的知识并不完整。肥胖患者的病理生理变化可能导致氨基糖苷类药物血浆浓度低于或高于治疗水平,尤其是在存在脓毒症的情况下。需要进行严格的临床研究,以建立危重症肥胖脓毒症患者的氨基糖苷类药物给药指南。

相似文献

1
Pharmacokinetic changes and dosing modification of aminoglycosides in critically ill obese patients: a literature review.
J Clin Med Res. 2014 Aug;6(4):227-33. doi: 10.14740/jocmr1858w. Epub 2014 May 22.
2
Aminoglycoside Dosing and Volume of Distribution in Critically Ill Surgery Patients.
Surg Infect (Larchmt). 2020 Dec;21(10):859-864. doi: 10.1089/sur.2020.012. Epub 2020 Apr 17.
3
Aminoglycosides in the Intensive Care Unit: What Is New in Population PK Modeling?
Antibiotics (Basel). 2021 Apr 29;10(5):507. doi: 10.3390/antibiotics10050507.
5
Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility.
Expert Rev Anti Infect Ther. 2017 Jun;15(6):519-526. doi: 10.1080/14787210.2017.1316193. Epub 2017 Apr 17.
6
Experience with a once-daily dosing program of aminoglycosides in critically ill patients.
Intensive Care Med. 2002 Jul;28(7):936-42. doi: 10.1007/s00134-002-1313-7. Epub 2002 May 30.
7
Comprehensive Guidance for Antibiotic Dosing in Obese Adults.
Pharmacotherapy. 2017 Nov;37(11):1415-1431. doi: 10.1002/phar.2023. Epub 2017 Oct 30.
8
Aminoglycosides in critically ill patients: which dosing regimens for which pathogens?
Int J Antimicrob Agents. 2020 Oct;56(4):106124. doi: 10.1016/j.ijantimicag.2020.106124. Epub 2020 Jul 31.
9
Aminoglycoside dosing considerations in intensive care unit patients.
Ann Pharmacother. 1993 Mar;27(3):351-7. doi: 10.1177/106002809302700319.
10
Population pharmacokinetics of aminoglycosides in critically ill trauma patients on once-daily regimens.
J Trauma. 2000 Nov;49(5):869-72. doi: 10.1097/00005373-200011000-00013.

引用本文的文献

2
Individual pharmacokinetic parameter estimation of gentamicin in an obese hemodialysis patient using non-linear mixed effect model.
Transl Clin Pharmacol. 2024 Sep;32(3):150-158. doi: 10.12793/tcp.2024.32.e14. Epub 2024 Sep 25.
3
Updated antimicrobial dosing recommendations for obese patients.
Antimicrob Agents Chemother. 2024 May 2;68(5):e0171923. doi: 10.1128/aac.01719-23. Epub 2024 Mar 25.
4
Therapeutic Drug Monitoring of Antimicrobials in Critically Ill Obese Patients.
Antibiotics (Basel). 2023 Jun 24;12(7):1099. doi: 10.3390/antibiotics12071099.
5
Is fat-free mass-based gentamicin dosing regimen preferable than whole-body weight in neonates?
Pediatr Investig. 2023 Jun 8;7(2):86-94. doi: 10.1002/ped4.12386. eCollection 2023 Jun.
8
Aminoglycosides in the Intensive Care Unit: What Is New in Population PK Modeling?
Antibiotics (Basel). 2021 Apr 29;10(5):507. doi: 10.3390/antibiotics10050507.

本文引用的文献

1
Aminoglycoside dosing in patients by kidney function and area under the curve: the Sawchuk-Zaske dosing method revisited in the era of obesity.
Diagn Microbiol Infect Dis. 2014 Feb;78(2):178-87. doi: 10.1016/j.diagmicrobio.2013.10.011. Epub 2013 Oct 22.
2
Evaluation of extended interval dosing aminoglycosides in the morbidly obese population.
Adv Pharmacol Sci. 2013;2013:194389. doi: 10.1155/2013/194389. Epub 2013 Aug 19.
3
Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients.
Antimicrob Agents Chemother. 2011 Sep;55(9):4006-11. doi: 10.1128/AAC.00174-11. Epub 2011 Jun 13.
4
Antibiotic dosing in critical illness.
J Antimicrob Chemother. 2011 Apr;66 Suppl 2:ii25-31. doi: 10.1093/jac/dkq516.
5
Pharmacotherapy in the critically ill obese patient.
Crit Care Clin. 2010 Oct;26(4):679-88. doi: 10.1016/j.ccc.2010.07.003.
7
Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock.
Crit Care. 2010;14(2):R53. doi: 10.1186/cc8945. Epub 2010 Apr 6.
8
Effect of obesity on the pharmacokinetics of drugs in humans.
Clin Pharmacokinet. 2010;49(2):71-87. doi: 10.2165/11318100-000000000-00000.
9
A new equation to estimate glomerular filtration rate.
Ann Intern Med. 2009 May 5;150(9):604-12. doi: 10.7326/0003-4819-150-9-200905050-00006.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验